Metastatic or locally advanced basal cell carcinoma

The PBS subsidises vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

Vismodegib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with metastatic or locally advanced basal cell carcinoma.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria..

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing vismodegib.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised vismodegib for the treatment of metastatic or locally advanced BCC in writing and:

All applications must include a completed:

Continuing treatment

Make all applications for authority approval to continue PBS subsidised vismodegib for the treatment of metastatic or locally advanced BCC in writing and:

All applications must include a completed:

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 October 2017